Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 21. Novel 4-Alkoxy and 14-Phenylpropoxy Derivatives of the μ Opioid Receptor Antagonist Cyprodime
- 8 May 2004
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (12) , 3242-3247
- https://doi.org/10.1021/jm031126k
Abstract
The synthesis, biological, and pharmacological evaluation of novel derivatives of cyprodime are described. Their binding affinities at μ, δ, and κ opioid receptors were evaluated using receptor binding assay. It was observed that the affinity of these compounds was sensitive to the character and length of the substituent in position 4. Further prolongation of the 4-alkoxy group of cyprodime (1) and its 4-butoxy analogue 2 is detrimental for the μ opioid receptor affinity. Introduction of an arylalkoxy group at C-4 does not increase μ affinity in the case of benzyloxy, while a phenylpropoxy group reduces μ affinity. The δ and κ affinities were also reduced compared to the reference compounds. A significant increase in the affinity at the μ opioid receptors was achieved by introducing a 14-phenylpropoxy group. Increases in the affinity at δ and κ receptors were also observed. These findings provide further evidence that the nature of the substituent at position 14 has a major impact on the abilities of morphinans to interact with opioid receptors. In the [35S]GTPγS binding assay, all tested compounds were partial agonists at μ and δ receptors. Compounds 8 and 17 showed antagonism at κ receptors, while compound 7 exhibited some partial agonist activity at this receptor. The novel derivatives of cyprodime containing a 14-phenylpropoxy group acted as potent antinociceptives. When tested in vivo, compounds 7, 8, and 17 were considerably more potent than morphine, with phenol 7 showing the highest antinociceptive potency (21-fold in the hot plate test, 38-fold in the tail flick test, and 300-fold in the paraphenylquinone writhing test) in mice. Introduction of a 14-phenylpropoxy substituent leads to a profound alteration in the pharmacological profile of this class of compounds.Keywords
This publication has 17 references indexed in Scilit:
- Modulation of melanocortin-induced changes in spinal nociception by μ-opioid receptor agonist and antagonist in neuropathic ratsNeuroReport, 2002
- Involvement of μ - and κ -, but not δ -, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestineBritish Journal of Pharmacology, 2002
- Binding, pharmacological and immunological profiles of the δ-selective opioid receptor antagonist HS 378Life Sciences, 2001
- Interaction of agonist peptide [3H]Tyr-d-Ala-Phe-Phe-NH2 with μ-opioid receptor in rat brain and CHO-μ/1 cell linePeptides, 1998
- Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 11. 3-Hydroxycyprodime and Analogs: Opioid Antagonist Profile in Comparison to CyprodimeJournal of Medicinal Chemistry, 1995
- Tritium Labelling of Cyprodime ( = (—)‐17‐(Cyclopropylmethyl)‐4,14‐dimethoxymorphinan‐6‐one), a μ Receptor‐Selective Opioid AntagonistHelvetica Chimica Acta, 1992
- Synthesis and Biological Evaluation of 14‐Alkoxymorphinans, V1): 6‐Deoxocyprodime, an Opioid Antagonist with Decreased μ Receptor Selectivity in Comparison to CyprodimeArchiv der Pharmazie, 1991
- Synthesis and biological evaluation of 14-alkoxymorphinans. 3. Extensive study on cyprodime-related compoundsJournal of Medicinal Chemistry, 1990
- Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(Cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective .mu. opioid receptor antagonistJournal of Medicinal Chemistry, 1989
- New synthesis of .beta.-lactams based on nitrone cycloaddition to nitroalkenesThe Journal of Organic Chemistry, 1984